Bridgebio Pharma Inc. kept the phase III wins coming, this time with positive top-line results from Propel 3, the global phase III pivotal study of oral infigratinib, designed to inhibit FGFR3 signaling in children with achondroplasia. Read More
Viking Therapeutics Inc. said after-market hours Feb. 11 that it plans to advance its oral dual GLP-1/GIP receptor, VK-2735, into a phase III trial for obesity in the third quarter of 2026. VK-2735 is a novel dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonist. Read More
After closing an oversubscribed $85 million series B round, Quantx Biosciences Inc. is gearing up to begin clinical trials of its two lead immunology compounds, a STAT6 oral small-molecule inhibitor and an IL-17 oral small-molecule inhibitor. Read More
The pressure to replace animal testing with human-relevant assays that are more predictive of human-drug responses has now reached a tipping point, and there is a movement toward greater acceptance of these potentially more translatable tests. Read More
Med-tech companies looking for capital will have to work harder this year to attract investor attention. Even though investment firms have money to deploy, the capital will go toward more targeted opportunities and later-stage companies. For early stage med tech, 2026 is expected to be a tough year, which is raising concerns about the pipeline of innovative technologies in the long term. Read More
After a prolonged downturn, the med-tech IPO market rebounded in 2025, with deal value surging to $13.01 billion across 31 offerings. The recovery followed two muted years, with just $619 million raised in 2024 and a low-point of $110 million in 2023. Read More
Undeterred by all the unsuccessful biopharma suits challenging the U.S. Medicare price negotiations, Abbvie Inc. filed its own complaint Feb. 11 in the U.S. District Court for the District of Columbia, seeking to undo CMS’ selection of Botox in the third round of the negotiations. Read More
Beginning Feb. 2, 2026, medical technology news and analysis will be integrated into BioWorld, where curated coverage will continue as part of BioWorld’s core reporting. Read More
Biopharma and med-tech companies raising money in public or private financings, including: Aim Immunotech, Avicanna, Envoy, Evogen, Galecto, Insight Molecular, Nasus, Neogap, Wellumio. Read More
Clinical updates for biopharma and med tech, including data readouts and publications: Bioxytran, Eccogene, Heparegenix, Intrabio, Heparegenix, Upstream. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Biocodex, Calbiotech, Formycon, Helsinn, Liquid, Lotus, Magnapharm, Owlet, Theranexus. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Agilent, Biocardia, Biofrontera, Biorestorative, GSK, Immune, Moderna, Outlook, Regenxbio, Takeda, Zoll. Read More
.webp?t=1770931681 "Interleukin 17 (IL-17)")
